

COVID-19 Testing Algorithm (1st Analysis)

TESTING: COVID-19 Testing Algorithm



COVID-19 Testing Algorithm (Control Analysis)

CONTROL: COVID-19 Testing Algorithm



The government of Rwanda through the National Reference Laboratory (NRL)/Rwanda Biomedical Center (RBC) has the capacity to screen and confirm suspected COVID-19 cases. Routine confirmation of COVID-19 cases is based on the detection of SARS-Cov-2 nucleic acid (RNA) by real time RT-PCR assays. The current recommended sample is Oropharyngeal swabs collected in viral transport medium (VTM) that inactivates the virus to minimize risk of infection

The current testing algorithm for screening and confirmation testing of COVID-19 cases recommends performing two RT-PCRs based on the detection of specific and nonspecific COVID-19 genes:

- Detection kit for 2019 Novel Coronavirus (2019-mCoV) RNA (PCR-Fluorescence Probing): it is a multiplex RT-PCR assay based on the detection of ORF1a, ORF1b and N gene
- LightMix SarbecoV E-gene plus EAV control; based on the detection of E gene that detects SARS and 2019-nCOV virus
- LightMix Modular SARS-CoV-2 (COVID19) RdRp: based on the detection of a conserved region of the RNA-dependent RNA polymerase (RdRp) gene that detects SARS-CoV-2 specific FA; labeled hydrolysis probe. The assay detects Wuhan origin 2019-nCOV virus but not all other SARS-like viruses.

Summary of the COVID-19 testing workflow:

- 1. RNA extraction using Manuel and automated protocols
- 2. Initial diagnostic testing (Screening) with the RT-PCR using the Detection kit for 2019 Novel Coronavirus (2019-nCoV) RNA (PCR-Fluorescence Probing). nRL is prioritizing - This assay as the first screening test because it has demonstrated slightly higher sensitivity for the detection of COVID-19
- 3. If negative, the patient is considered not infected with COVID-19 and the result is reported to the requesting healthcare worker/site
- 4. If positive on 2019-nCoV RNA, the LightMix SarbecoV E-gene and LightMix Modular SARS-CoV-2 (COVID19) RdRp RT-PCRs are simultaneously performed on the RNA extract as confirmation test
- 5. If positive on the LightMix SarbecoV E-gene and LightMix Modular SARS-CoV-2 (COVID19) RdRp RT-PCRs, the patient is confirmed to have COVID-19 infection and referred for treatment to isolation centers
- 6. If 2019-nCoV positive, LightMix SarbecoV E-gene and LightMix Modular SARS-CoV-2 (COVID19) RdRp negatives, the case is considered as presumptive positive repeat testing on a fresh sample collected after 3 days
- 7. If 2019-nCoV positive, and only LightMix SarbecoV E-gene is positive and LightMix Modular SARS-CoV-2 (COVID19) RdRp is negative, the case is considered as presumptive positive, repeat testing on a fresh sample collected after 3 days
- 8. If 2019-nCoV positive, and only LightMix SarbecoV E-gene is negative and LightMix Modular SARS-CoV-2 (COVID19) RdRp is positive (rare case), then repeat the analysis as there might be error in the Lab during sample processing.

For control analysis, only LightMix SarbecoV kit should be used for testing E-gene and RdRp gene. In case both genes are positive (CT values <40 cycles) the result is reported positive and patient should remain in isolation and treatment centre. When both E-gene and RdRp gene are negative (CT values >40 cycles), the test is declared negative and will be repeated after 3 days (WHO guidelines) before to discharge the patient.

In case E-gene is positive (CT values <40 cycles) and RdRp negative (CT values >40 cycles), the test can be declared negative if E-gene CT value is close to 40 cycles (e.g. CT=38) and the physician can decide to discharge the patient based on his/her clinical conditions and self-isolation at home is highly recommended until the lab gets a second negative analysis after 72 hours (3 days).

PS: if the patient is admitted to isolation centers, take a sample for acute serology. 5mL serum tube or plain (no additive) tube and 5mL EDTA and heparin tube, respectively; for children <12 years 1mL is acceptable.